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Abstract
Purpose Our objective was to estimate the economic out-
comes of using mirabegron versus antimuscarinics in the
treatment of patients with overactive bladder (OAB) from a
societal perspective in the UK.
Materials and Methods A Markov model was developed
using Microsoft Excel. The time horizon and cycle length
are 12 and 1 months, respectively; and the hypothetical
cohort size 100 patients. Antimuscarinic comparators are
fesoterodine, oxybutynin extended release (ER) and
immediate release (IR), solifenacin, tolterodine ER/IR,
trospium ER/IR, darifenacin and flavoxate. Model inputs
included real-world treatment patterns data, healthcare
resource use (e.g. clinic visits) and direct and indirect costs
(e.g. drug acquisition and productivity loss). Model outputs
included patient disposition, healthcare resource use, drug
acquisition costs and other treatment-related costs over a
1-year time horizon. A one-way sensitivity analysis was
performed to determine the key drivers of the model.
Results In a hypothetical cohort of 100 patients, total
annual costs per patient were lower with mirabegron than
with all antimuscarinics (£1270.84 vs. 1321.71–1607.48).
Healthcare resource use was lower with mirabegron than
with all antimuscarinics (115 vs. 119–123 general practi-
tioner visits; 173 vs. 178–185 specialist visits and 0.0042
vs. 0.0050–0.0060 surgical operations) and fewer work
hours were lost (4017 vs. 5114–6990 [all per 100 patients]).
Sensitivity analysis showed the model was sensitive to
persistence and switching rates, although the impact on the
overall results was minimal.
Conclusions In the UK, using mirabegron to treat OAB
may improve persistence and lead to reductions in
switching treatment, healthcare resource utilization, pro-
ductivity costs, and overall treatment costs versus
antimuscarinics.
Key Points for Decision Makers
Treatment of overactive bladder (OAB) with
mirabegron 50 mg in the UK may result in lower
healthcare resource utilization, lost productivity
costs, and overall treatment costs compared with
antimuscarinics.
Further work is needed to confirm these findings in
different populations to assess the effects of
mirabegron on the costs of treatment in other
countries.
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1 Introduction
Overactive bladder (OAB) is characterized by urinary
urgency, usually with urinary frequency and nocturia, with
or without urinary incontinence [1]. OAB affects up to 17%
of adults aged C40 years in Europe and up to 17% of all
adults in the USA [2, 3]. In Europe, a higher proportion
(30–40%) of OAB is observed in adults C75 years of age
[2].
The clinical and economic burden of OAB is significant.
Symptoms of OAB have been reported to adversely affect
patients’ daily activities, sleep, mental health and personal
relationships [4, 5]. These symptoms also have a significant
impact on productivity in the workplace and healthcare
resource use [6]. In the UK, the total direct economic
impact (incremental costs) of OAB on the national
healthcare system is estimated to be in excess of £1 billion
[6].
Following the use of conservative management strate-
gies, treatment with pharmacotherapy can result in symp-
tom improvement. However, bothersome on-treatment
adverse events (AEs) from antimuscarinic agents (such as
dry mouth and constipation) are common because of a lack
of target organ specificity [7]. Side effects observed with
antimuscarinics may also have deleterious effects on
treatment persistence. A screening survey conducted in the
USA identified 6577 patients with one or more antimus-
carinic prescriptions for OAB [8]. Of the 1322 patients who
reported discontinuing treatment prior to follow-up, 1177
(89%) discontinuations were primarily due to unmet
treatment expectations and/or tolerability [8].
Mirabegron is a first-in-class licensed selective oral b3-
adrenoceptor agonist approved in the UK for the treatment
of OAB [9]. It promotes bladder relaxation of the detrusor
muscle during the storage phase, improving bladder
capacity [10]. Mirabegron demonstrated overall efficacy
similar to that of antimuscarinic therapies in clinical trials
[11] but with an improved overall tolerability profile
[11, 12]. Evidence from a recent retrospective analysis of
prescription claims in Canada demonstrated that, over a
12-month period, patients with OAB treated with mirabe-
gron have improved persistence compared with those
treated with antimuscarinics [13].
A prospective study of women with OAB who received
treatment with fesoterodine for 8 weeks also showed that



















Fig. 2 Treatment pathway
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greater improvements in clinical symptoms at the end of
the treatment period than those who were non-adherent
[14]. In addition, persistence with treatment has been
shown to reduce consumption of healthcare resources in
OAB [15]. Given the impact of OAB on work absen-
teeism and productivity [6], persistence and symptom
control may be expected to reduce the impact of these
factors.
This study aimed to use predominantly real-world evi-
dence to estimate the economic outcomes associated with
persistence with mirabegron treatment versus antimus-
carinic agents in patients with OAB in the UK.
2 Methods
2.1 Model Overview
This is a Microsoft Excel-based (version 17.0, Microsoft
Corporation, Redmond, WA, USA) Markov model. The
time horizon is 12 months, the cycle length is 1 month and
the default cohort size is 100 patients. Mirabegron
50 mg/day is compared with the following antimuscarinic
treatments (all doses reported are per day): fesoterodine
4/8 mg, oxybutynin extended release (ER) 5 mg, oxybu-
tynin immediate release (IR) 5 mg, solifenacin 5/10 mg,
Table 1 Model assumptions
Non-persisters were assumed to either switch, undergo surgical operations or remain uncontrolled
Switchers and patients having surgical operations were assumed to have controlled symptoms
At treatment initiation (the start of the model), all patients were assumed to incur one visit to a GP and 1.5 visits to a specialist (urologist) [17]
Switchers were assumed to have one GP visit, 1.5 visits to a specialist (urologist) and one urodynamic test [17]
Patients who switched treatment were ascribed a drug acquisition cost, which was weighted by the market share of each treatment. The market
share data were provided by Astellas [24]
One total probability of surgical operations was included and costs were applied [19], assuming that 50% of patients had onabotulinumtoxinA
injection and 50% had SNS
Only non-persisters with uncontrolled symptoms were assumed to be at risk of co-morbidities (depression and UTI) [25]; the risk was applied
in each cycle
Patients who were non-persistent and uncontrolled were assumed to have a 21.1% decrease in hours worked [25]
The persistence at 12 months was assumed to be the same for each treatment irrespective of the dose received [16]
The persistence at 12 months was assumed to be the same for trospium ER and IR formulations, and tolterodine ER and IR [16]
ER extended release, GP general practitioner, IR immediate release, SNS sacral nerve stimulation, UTI urinary tract infection
Table 2 Clinical inputs Variable Value (%) Source
Proportion of patients with incontinence 60.00 Nitti et al. [22]a
Percentage of patients switching treatment 26.06 Nazir et al. [17]
12-month persistence (UK CPRD)
Mirabegron 50 mg 37.70 Astellas [16]
Fesoterodine 4/8 mg 24.00 Astellas [16]
Oxybutynin ER 5 mg 17.20 Astellas [16]
Oxybutynin IR 5 mg 12.40 Astellas [16]
Solifenacin 5/10 mg 24.80 Astellas [16]
Tolterodine ER 4 mg 20.60 Astellas [16]
Tolterodine IR 4 mg 20.60 Astellas [16]
Trospium ER 60 mg 19.10 Astellas [16]
Trospium IR 40 mg 19.10 Astellas [16]
Darifenacin 7.5 mg 15.90 Astellas [16]
Flavoxate 600 mg 8.30 Astellas [16]
General population mortality 0.97 ONS [18]
CPRD Clinical Practice Research Datalink, ER extended release, IR immediate release, ONS Office for
National Statistics
a A conservative estimate of 60% was applied to the model based on 65.7% of the total population who
were reported to have urgency or mixed incontinence at baseline. All doses reported are the total dose per
day
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tolterodine ER or IR both 4 mg, trospium ER 60 mg or IR
40 mg, darifenacin 7.5 mg, and flavoxate 600 mg.
The base-case analysis provided a societal perspective
of OAB management by accounting for all costs incurred
by the UK NHS as well as those associated with lost pro-
ductivity. Patient disposition, healthcare resource use,
direct costs, indirect costs and total costs were all assessed
as part of the base-case analysis.
2.2 Treatment Pathway
Patients enter the model in the ‘persistence on treatment’
health state (Fig. 1) and are assigned to treatment with
mirabegron 50 mg (the recommended approved dose in
the UK [9]) or an antimuscarinic agent (Fig. 2). At the
end of each month, patients either persist with treatment
or discontinue. Those who discontinue initial treatment
switch to an alternative pharmacological intervention,
undergo surgical operations (onabotulinumtoxinA injec-
tion or sacral nerve stimulation [SNS]) or discontinue
treatment altogether. Patients can transition to other
treatment states or death at each cycle. To make the
analysis tractable within a 12-month time horizon, the
model assumes that switching to a second-line pharma-
cotherapy and undergoing surgical operations both lead
to symptom control (with no option for additional lines
of treatment) until the end of the time horizon. Patients
who discontinue treatment altogether are assumed to
Table 3 Resource inputs
Parameter Value or probability Unit cost Source
Drug acquisition Cost per day (£)
First-line pharmacotherapy –
Mirabegron 50 mg – 0.97 BNF 71 [23]
Fesoterodine 4/8 mg – 0.92 BNF 71 [23]
Oxybutynin ER 5 mg – 0.46 BNF 71 [23]
Oxybutynin IR 5 mg – 0.07 BNF 71 [23]
Solifenacin 5/10 mga – 1.00 BNF 71 [23]
Tolterodine ER 4 mg – 0.92 BNF 71 [23]
Tolterodine IR 4 mg – 0.09 BNF 71 [23]
Trospium ER 60 mg – 0.82 BNF 71 [23]
Trospium IR 40 mg – 0.83 BNF 71 [23]
Darifenacin 7.5 mg – 0.91 BNF 71 [23]
Flavoxate 600 mg – 0.39 BNF 71 [23]
Second-line pharmacotherapyb – 0.64 BNF 71 [23], Astellas [24]
Surgical operationsc 0.01% 1242.59
Visits/test
GP 1 46.89 Nazir et al. [19]; PSSRU [21]
Urologist 1.5 102.16 Nazir et al. [19]; UK Department of Health
Urodynamic test 1 282.00 Nazir et al. [19]; South Devon Healthcare [30]
Pads Cost per pad (£)
On treatment 2.5/day 0.25 Nazir et al. [19]; Incontinence Direct [31]
Off treatment 5.5/day 0.25 Nazir et al. [19]; Incontinence Direct [31]
Co-morbidities
Depression 19.0%d 99.10 Arlandis-Guzman et al. [25]; Irwin et al. [6]
UTI 30.7%d 2.79 Arlandis-Guzman et al. [25]; Irwin et al. [6]
All doses reported are the total dose per day
BNF British National Formulary, ER extended release, GP general practitioner, IR immediate release, OAB overactive bladder, UTI urinary tract
infection
a Weighted average of solifenacin 5 mg (70%) and 10 mg (30%); unit costs of 30 tablet packs of £27.62 and £35.91, respectively
b Weighted cost based on market share of oral therapies for OAB
c Weighted cost based on a 50:50 ratio of onabotulinumtoxinA and sacral nerve stimulation
d 6-month probability; unit costs based on 2005 monthly costs, converted to 2015 values using the UK forex exchange rate (as of October 2015)
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remain uncontrolled. Other model assumptions are
reported in Table 1.
2.3 Model Input Parameters
2.3.1 Clinical Inputs
We derived 12-month persistence data (Table 2) from a
retrospective database study conducted in the UK [16]. In
addition, the treatment switching rate (26.06%) was taken
from a previously published cost-effectiveness analysis of
mirabegron compared with antimuscarinics for the treat-
ment of adults with OAB in the UK [17]. Mortality for the
population with OAB was based on the UK age-standard-
ized general population mortality rate [18] and converted to
a 1-month probability (P) using the formula: P = 1 - e-rt,
where r represents rate and t time.
2.3.2 Healthcare Resource Use
Costs associated with resource use such as general practi-
tioner (GP) and specialist visits were derived from NHS
data [19–21]. Unit costs were calculated/estimated for one
GP visit and 1.5 referrals to a urologist at treatment initi-
ation and treatment switch (Table 3) [17]. One test by a
specialist clinician (e.g. urologist, gynaecologist or other)
was performed for each patient who switched to a second-
line pharmacotherapy [17]. The proportion of patients with
incontinence and requiring pads was estimated to be 60%
based on the number of patients with wet OAB [22]. Pad
use was estimated to be 2.5 pads per day for patients on
treatment (i.e. persisters and switchers) and 5.5 pads per
day for those off treatment (i.e. those who underwent
surgical operations or discontinued all treatment) [19].
Drug acquisition costs were calculated based on the
treatment cost per pack (Table 3) [23] and were correct as
of quarter 1, 2016. The cost of second-line pharmacother-
apy was based on a weighted average derived from UK
market share data [24].
Patients who were uncontrolled were considered to be at
risk of two co-morbidities: depression and urinary tract
infection (UTI). The 6-month probabilities of depression
and UTI were 18.8 and 30.7%, respectively [25], and the
monthly probability of surgical operations was 0.01% [17].
The costs for all resources were based on 2015 values,
or inflated to 2015 values using the consumer price index
(CPI) where applicable. The costs of depression and UTI
sourced from Irwin et al. [6] were converted from € to
British  using the UK Forex exchange rate (as of
December 2015).
2.3.3 Loss of Productivity
The model accounts for loss of work productivity only in
patients who are non-persistent with treatment, have
uncontrolled symptoms and are in employment. The base-
case analysis assumed that 34.7% of the patients were
employed for an average of 40 h per week [25, 26], had
uncontrolled OAB and had a 21.1% reduction in the hours
worked [25]. The average hourly wage of £12.62 (2011









































































































Persisters at 1 year Switchers at 1 year Non-persisters at 1 year
Fig. 3 Summary of patient disposition after 12 months for each treatment. Total disposition may not sum to 100% because of rounding. All
doses reported are the total dose per day. ER extended release, IR immediate release
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2.4 Sensitivity Analysis
A one-way univariate deterministic sensitivity analysis
(DSA) was performed to assess the uncertainty of chosen
parameters [28]. Here, a standard 20% variation in the
following model parameters was tested individually and
the effects on the incremental costs determined: persis-
tence at 12 months, percentage of patients switching and
probability of surgical operations. Mirabegron 50 mg was
compared with solifenacin 5/10 mg and oxybutynin IR
5 mg. The results of the DSA were presented as a tornado




After 12 months, more patients persisted on treatment with
mirabegron 50 mg than with all antimuscarinics (39 vs.
9–26%, respectively [values for all antimuscarinics pre-
sented as a range]) (Fig. 3). This resulted in fewer patients
either switching treatment (16 vs. 19–23%, respectively) or
becoming non-persistent uncontrolled patients (44 vs.
54–66%, respectively).
3.2 Healthcare Resources
Resource use was lower with mirabegron 50 mg than with
all antimuscarinics, including GP visits (115 vs. 119–123,
respectively, per 100 patients), specialist visits (173 vs.
178–185, respectively, per 100 patients) and number of
surgical operations (0.0042 vs. 0.0050–0.0060, respec-
tively, per 100 patients) (Table 4). Total pad use per
patient over 12 months was also lower with mirabegron
50 mg than with all antimuscarinics (71,807 vs.
76,531–84,602, respectively, per 100 patients) (Fig. 4).
3.3 Direct Costs
Mirabegron 50 mg had a higher medication cost than all
antimuscarinics (£24,744 vs. 4599–22,634 per 100
patients) (Table 5). However, resource use costs, including
those for the co-morbidities of depression and UTI, GP
visits, specialist visits, surgical operations, urodynamic
tests and pads, were lower with mirabegron than with all
antimuscarinics (Table 5).
3.4 Indirect Costs
The number of work hours lost (4017 vs. 5114–6990 per
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vs. 71,284–97,430 per 100 patients) were both lower with
mirabegron 50 mg than with all antimuscarinics (Fig. 5).
3.5 Total Costs
Total costs were lower for mirabegron 50 mg than for all
antimuscarinics (£127,084 vs. 132,171–160,748, respec-
tively, per 100 patients) (Fig. 6). This translated into lower
respective total costs per patient (£1271 vs. 1322–1607)
and per patient per day (£3.48 vs. 3.62–4.40).
3.6 Sensitivity Analysis
For both comparisons, the model was most sensitive
to ± 20% changes in persistence rates for either treatment
and the percentage of patients switching (Fig. 7). The
incremental cost savings per patient per day were -£0.45
in the base-case analysis of mirabegron 50 mg versus
solifenacin 5/10 mg and -£0.55 versus oxybutynin IR
5 mg. The overall impact was similar when the incremental
cost savings per additional patient persisting on treatment
were assessed (Fig. S1 in the Electronic Supplementary
Material).
4 Discussion
To our knowledge, this model is the first to estimate the
economic impact of using mirabegron 50 mg versus
antimuscarinic agents for the treatment of OAB from a
societal perspective in the UK, largely employing real-
world data (specifically persistence rates).
According to the model, after 12 months, more patients
receiving mirabegron 50 mg versus all antimuscarinics
persisted with treatment, fewer patients switched treatment
and fewer work hours were lost. Although mirabegron
50 mg had higher medication costs over 12 months than
did antimuscarinics, these costs were offset by savings
attributed to other direct and indirect costs. This was partly
attributable to a lower proportion of non-persisters and
switchers, who had higher demand for healthcare resources
and higher pad use than patients who persisted with treat-
ment. The results suggest that more patients in the UK who
receive mirabegron will persist with first-line pharmaco-
logical treatment versus antimuscarinics over 12 months,
resulting in more patients with likely controlled symptoms.
Administration of mirabegron as first-line pharmacother-
apy for OAB could have beneficial effects in terms of
lower resource use and overall treatment, containment of
healthcare costs and societal benefit. Furthermore, while
lower healthcare resource use has been cited as a benefit of
increased treatment persistence [15], better persistence
rates could also be expected to improve patient quality of
life (QoL), likely because of increased symptom control
and an increased ability to continue daily activities [15].
This model did not include the likely improvements in QoL
for those who persist with treatment.
While similar efficacy is observed between mirabegron
and antimuscarinics [11], real-world evidence indicates
that a higher proportion of patients are likely to be non-
persistent with treatment with antimuscarinics versus mir-
abegron 50 mg [13]. Potential reasons for treatment dis-
continuation with antimuscarinics include bothersome AEs
such as dry mouth and constipation, the most common AEs
in these patients [7]. A recent systematic literature review
and network meta-analysis of mirabegron 50 mg versus
antimuscarinics in 27,309 patients with OAB reported a

































































































Fig. 4 Total pad use per 100 patients, after 12 months for each treatment. All doses reported are the total dose per day. ER extended release, IR
immediate release






































































































































































































































































































































































































































































































































































































































































































































































































































































32 J. Nazir et al.
placebo but a lower incidence for mirabegron 50 mg versus
all antimuscarinics assessed [11]. These findings may be
reflected in the present study, as healthcare resource use
was lower for mirabegron 50 mg than for all antimus-
carinics, with fewer associated costs. However, it should be
noted that treatment discontinuation can be attributed to
many factors, and a greater overall focus should be applied
to tailoring OAB treatment to the individual.
The primary strengths of this model are that it utilizes
real-world data related to treatment of OAB and healthcare
resource use in the UK. Therefore, the total costs derived
for mirabegron versus antimuscarinics are based on effec-
tiveness rather than efficacy. However, the findings that
suggest a benefit of mirabegron (if used as first-line phar-
macotherapy for OAB) depend on the several key
assumptions made in the model, such as persistence at
12 months being independent of the treatment dose
received and persistence not varying between trospium ER
and IR and tolterodine ER and IR. Furthermore, all patients
who switch treatment or undergo surgical operations are
assumed to have controlled symptoms, and this would be
variable. Structural edits to the model would be required to
account for these factors if additional sensitivity analyses
were to be performed. As OAB is a chronic condition,
provision of a longer time horizon would be beneficial to
accurately estimate the economic benefits of long-term
treatment. Another limitation is that no direct clinical data
for estimates of efficacy, tolerability or health-related QoL
were included; therefore, some patient perspectives were






























































































































Fig. 5 Total work hours lost over 12 months and associated costs for each treatment per 100 patients. All doses reported are the total dose per









































































































Fig. 6 Total costs (including indirect costs) over 12 months for each treatment per 100 patients. All doses reported are the total dose per day. ER
extended release, IR immediate release
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the model includes the most common treatment options for
OAB in the UK according to the results of a retrospective
analysis of a clinical practice database [16]; this included
flavoxate, which is not recommended for use in women
with urinary incontinence in the UK [29].
Although the model does not account for persistence in
different subgroups of patients, results were largely con-
sistent with the total study population, and few differences
in persistence between subgroups were observed in a
Canadian study of persistence with mirabegron 50 mg
versus antimuscarinics over 12 months (the only
notable difference was that patients were more likely to
persist as the number of co-existing prescribed medications
increased [up to more than eight]) [13]. Whether differ-
ences between subgroups would be observed if the model
were updated to allow these kinds of analyses is unclear.
The persistence data used in the model were taken from a
large non-interventional study conducted in the UK [16];
Incremental results lower (-20 %)
Incremental results higher (+20 %)
Incremental cost per patient per day
(£; mirabegron vs comparator)
-0.90 -0.80 -0.70 -0.60 -0.50 -0.40 -0.30 -0.20 -0.10 -0.00
Incremental cost per patient per day
(£; mirabegron vs comparator)
-0.80 -0.70 -0.60 -0.50 -0.40 -0.30 -0.20 -0.10 0.00
Persistence rate (Mirabegron 50 mg)
Persistence rate (Oxybutynin IR 5 mg)
Persistence rate (Mirabegron 50 mg)
Persistence rate (Solifenacin 5/10 mg)
Percentage of patients switching
Probablity of surgery




Fig. 7 Results of the deterministic sensitivity analysis for mirabegron 50 mg versus a solifenacin 5/10 mg and b oxybutynin IR 5 mg
(incremental cost per patient per day). All doses reported are the total dose per day. IR immediate release
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patient demographics in this study were generally well-
balanced across treatment groups, although significantly
more patients receiving mirabegron were female, treat-
ment-experienced and receiving co-existing medications
compared with those receiving the primary comparator
treatment (tolterodine ER).
5 Conclusions
This model suggests that treatment of OAB in the UK with
mirabegron 50 mg will result in more patients persisting
with treatment and lower total costs of treatment versus
antimuscarinics. Further work is needed to confirm these
findings in different populations to assess the effect of
mirabegron on persistence and overall treatment costs in
other countries.
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